Immuneering Appoints Leah R. Neufeld as Chief People Officer
CAMBRIDGE, Mass., Oct. 20, 2022 (GLOBE NEWSWIRE) — Immuneering Corporation (Nasdaq:IMRX), a biopharmaceutical company that aims to create medicines for all patients with solid tumors driven by RAS mutations and other MAPK pathway activation events, today announced the appointment of Leah R. Neufeld to the newly created position of Chief People Officer, effective immediately.
Related news for (IMRX)
- MoBot’s Stock Market Highlights – 09/25/25 08:00 AM
- Spider Silk, Splicing & Strategic Capital: Biotech and Innovation Dominate the Morning Tape
- Immuneering Announces Pricing of $175 Million Underwritten Public Offering of Class A Common Stock and Concurrent $25 Million Private Placement of Class A Common Stock to Sanofi
- Don’t Miss Out: MoBot’s Latest Stock Updates 09/25/25 07:00 AM
- 24/7 Market News Snapshot 25 September, 2025 – Immuneering Corporation Class A Common Stock (NASDAQ:IMRX)